Borderline indications for ovarian suppression: addressing uncertainties with patients

Ovarian function suppression (OFS) is a potentially life-saving treatment for young women diagnosed with high-risk hormonal-receptor (HR)+ early breast cancer (EBC), albeit one associated with significant side effects that may adversely affect quality of life. Of particular concern, this article raises a few borderline indications that were largely unaddressed in pivotal clinical trials but are still commonly encountered in daily practice. These, referred to here as ‘borderline indications of OFS' remain a source of uncertainty for patients and physicians and are concisely addressed in this article.